Skip to Main Content

In a bid to speed the drug approval process, United States and European regulators reached an agreement to use each other’s inspection reports when reviewing production facilities.

The hope is “to avoid the duplication of drug inspections, lower inspection costs and enable regulators to devote more resources to other parts of the world where there may be greater risk,” according to a statement from the US Food and Drug Administration. The agency recently noted that, over the last five years, about 40 percent of its drug inspections were performed in the European Union.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!